Epidermodysplasia verruciformis (EV) is a rare genetic skin disorder that leaves a person abnormally vulnerable to a specific group of human papillomaviruses, leading to widespread, persistent wart-like growths and a high risk of skin cancer. Sometimes called “tree man syndrome” because of the bark-like lesions that can develop in severe cases, EV has drawn public fascination through a handful of dramatic case reports, but the underlying biology is far more nuanced than the headlines suggest. The condition sits at a strange intersection of genetics, virology, and immunology, and understanding how those threads come together explains both why EV looks the way it does and why treating it remains so difficult.
What Causes It
EV is driven by mutations in genes that most people have never heard of. The two best-studied culprits are EVER1 (also called TMC6) and EVER2 (TMC8), which sit next to each other on chromosome 17. Researchers identified these genes in the early 2000s when they found that people with EV carried disabling mutations in one or both of them.1Nature Genetics. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis The classic form of the disease follows an autosomal recessive pattern, meaning a person needs to inherit a defective copy from each parent. That is why consanguineous marriages, where both parents are more likely to carry the same rare mutation, show up disproportionately in EV families. A Japanese epidemiological survey found that 44% of EV patients came from families with consanguineous marriages.2Japanese Journal of Cancer Research. Epidemiologic Aspects of Epidermodysplasia Verruciformis (L-L 1922) in Japan
Not every EV case fits that neat recessive model. Rare cases have been linked to mutations in entirely different genes, including RHOH and MST1, which affect T-cell function rather than the EVER pathway.3PubMed Central. A case of classic epidermodysplasia verruciformis associated with elephantiasis: an atypical presentation There are also reports of families where the disease appears to follow an autosomal dominant pattern without any detectable EVER1 or EVER2 mutation at all, which suggests there are EV-causing genes still waiting to be found.4PubMed Central. Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation One case report documented a somatic mutation in the ANKRD26 gene in a young girl with severe EV, adding yet another gene to the growing list.5Wiley Online Library / PubMed Central. An ANKRD26 nonsense somatic mutation in a female with epidermodysplasia verruciformis (Tree Man Syndrome) The genetic picture, in short, is messier than the textbook version implies.
The Zinc Connection
For years after EVER1 and EVER2 were identified, nobody knew what the proteins they encode actually do. The breakthrough came when researchers discovered that EVER proteins form a complex with a zinc transporter called ZnT-1. Together, they regulate how zinc is distributed inside skin cells, particularly controlling the flow of free zinc into the cell’s nucleoli. They do not seem to change the total amount of zinc in a cell, but they change where it goes.6PubMed Central. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses
Why does zinc matter for a viral infection? Certain HPV proteins need zinc to function, and some rely on access to nuclear zinc to activate viral genes. When the EVER-ZnT-1 system works properly, it limits the free zinc available in parts of the cell that the virus needs. When EVER proteins are broken, that brake is gone, and the virus can hijack the cell’s zinc supply to replicate and persist. This is a highly specific vulnerability: it leaves the person defenseless against a particular family of HPVs but does not cause broad immune collapse. That selectivity is one of the most distinctive features of EV.
Which Viruses Are Involved
EV is not caused by the same HPV types that produce common warts on hands and feet or the high-risk strains linked to cervical cancer. Instead, it involves a distinct group known as beta-HPVs. Types 5 and 8 are the ones most strongly associated with EV and its cancer risk, though dozens of beta-HPV genotypes have been detected in EV patients.7PubMed Central. Genetic heterogeneity of oncogenic human papillomavirus type 5 (HPV5) and phylogeny of HPV5 variants associated with epidermodysplasia verruciformis Most healthy people actually carry beta-HPVs on their skin without ever developing symptoms. It is only when the host’s EVER-mediated defense is absent that these viruses gain a foothold and cause visible disease.
The relationship between the virus and the host in EV is unusually narrow. HPV 5 variants show no clear geographical clustering, which researchers think reflects the fact that the virus is restricted to a very specific host niche rather than spreading widely through populations.8PubMed Central. Genetic heterogeneity of oncogenic human papillomavirus type 5 (HPV5) and phylogeny of HPV5 variants associated with epidermodysplasia verruciformis In practical terms, someone with EV is not contagious in any meaningful sense: the viruses on their skin are the same ones already living harmlessly on most people’s skin. The problem is the host’s inability to keep them in check, not the presence of some exotic pathogen.
What It Looks Like
EV typically appears in childhood or early adolescence, though the age of onset varies. The skin findings fall into two broad patterns. The first is flat, wart-like papules, which may be skin-colored, pink, or brown and tend to cluster on the hands, arms, and face. The second is flat, scaly patches that resemble pityriasis versicolor, a common and unrelated fungal skin condition. These patches can be lighter or darker than the surrounding skin and often appear on the trunk and neck.9PubMed Central. Epidermodysplasia verruciformis mimicking pityriasis versicolor The visual resemblance between EV and pityriasis versicolor is close enough that misdiagnosis happens, especially in settings where dermatologists are less familiar with EV.
In severe cases, the lesions become thick, verrucous plaques that can coalesce into large masses, particularly on the hands and face. These are the cases that earn the “tree man” label in media reports. But most people with EV do not develop growths that dramatic. The more typical presentation is widespread but relatively flat lesions that, while disfiguring, are not physically debilitating in the way the most publicized cases suggest.
Telling EV apart from widespread flat warts caused by other HPV types (particularly HPV-3) is a genuine diagnostic challenge. Both conditions involve flat, wart-like lesions and can be associated with impaired cell-mediated immunity. Researchers have pointed out that the distinguishing features lean heavily on the specific HPV types detected and the presence of certain pigmented plaques, which are a particularly worrying prognostic sign in EV.10PubMed. Epidermodysplasia verruciformis versus disseminated verrucae planae: is epidermodysplasia verruciformis a generalized infection with wart virus? In practice, a biopsy and HPV genotyping are often needed to make the diagnosis with confidence.
The Cancer Risk
This is where EV becomes genuinely dangerous. Up to half of people with EV develop non-melanoma skin cancer, primarily squamous cell carcinoma, in sun-exposed areas.11Surgical and Experimental Pathology. Epidermodysplasia verruciformis: revision of a model of carcinogenic disease These cancers tend to arise in the third and fourth decades of life, decades after the initial skin lesions first appeared. Case reports describe squamous cell carcinoma developing on the face, forehead, and other chronically sun-exposed sites, sometimes alongside basal cell carcinoma.12PubMed Central. Case Report: Epidermodysplasia verruciformis with multiple squamous and basal cell carcinomas One report documented a large squamous cell carcinoma on the forehead of a 29-year-old woman with EV, illustrating how early these cancers can appear.13Our Dermatology Online. Giant squamous cell carcinoma in a patient with epidermodysplasia verruciformis
The mechanism behind the cancer risk involves a three-way interaction between the virus, ultraviolet radiation, and the host’s impaired immunity. HPV types 5 and 8 produce a protein called E6 that degrades ATR, a key enzyme involved in repairing DNA damage from UV light. When ATR is reduced, UV-induced DNA damage persists longer and accumulates, pushing cells toward malignant transformation.14PubMed Central. HPV 5 and 8 E6 Abrogate ATR Activity Resulting in Increased Persistence of UVB Induced DNA Damage Unlike cervical cancers driven by alpha-HPVs, where the viral genome is actively integrated into the tumor cells, EV-associated cancers seem to arise from a more indirect collaboration between the virus, UV exposure, and immune failure.15Surgical and Experimental Pathology. Epidermodysplasia verruciformis: revision of a model of carcinogenic disease
This makes sun protection genuinely important for EV patients, not as a cosmetic recommendation but as a cancer prevention strategy. The cancers strongly cluster in sun-exposed areas, and UV radiation is a confirmed co-factor in their development. Strict photoprotection from childhood onward is one of the few interventions that may meaningfully reduce the lifetime cancer burden.
Immune Findings in EV Patients
Although EV is fundamentally a genetic disorder of skin-cell zinc handling, immune abnormalities are part of the picture. Studies of EV patients have found lower numbers of T lymphocytes and T-helper cells in peripheral blood, even in patients without cancer. Interestingly, natural killer cell activity was elevated in some patients, while antibody-dependent cellular cytotoxicity remained normal.16Journal of the American Academy of Dermatology. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis These findings suggest a partial and selective immune deficit, not a wholesale immune collapse. The immune system is not failing broadly; it is failing specifically in the ways that matter for controlling beta-HPV infections in the skin.
This selective vulnerability helps explain why EV patients do not suffer from recurrent infections with other pathogens. They are not immunodeficient in the way that someone with advanced HIV is. Their immune gap is narrow enough that it only becomes apparent when specific HPV types exploit it.
Acquired EV in Immunocompromised People
Not everyone who develops EV-like skin lesions was born with the condition. A clinically similar picture, called acquired epidermodysplasia verruciformis (AEV), can develop in people whose immune systems are suppressed by other means. Organ transplant recipients on anti-rejection drugs, people living with HIV, patients on chemotherapy, and those taking certain biologic therapies for autoimmune diseases can all develop AEV.17PubMed Central. Acquired Epidermodysplasia Verruciformis in Patients with Iatrogenic Immunosuppression The same beta-HPV types, especially HPV 5 and 8, drive the lesions, but here the vulnerability comes from impaired cell-mediated immunity rather than from germline mutations in the EVER genes.
AEV carries its own cancer risk. Transplant recipients with AEV are at elevated risk for cutaneous squamous cell carcinoma, which is already a well-known concern in the transplant population broadly.18PubMed Central. Acquired Epidermodysplasia Verruciformis in Patients with Iatrogenic Immunosuppression People with vertically acquired HIV have also been reported to develop squamous cell carcinoma in the setting of EV-like skin changes.19Southern African Journal of HIV Medicine. Cutaneous squamous cell carcinoma in vertically acquired HIV and epidermodysplasia verruciformis The clinical overlap between genetic EV and AEV is extensive, and a careful history and sometimes genetic testing are needed to distinguish the two. The distinction matters because AEV can sometimes improve when the underlying immunosuppression is reversed or reduced, which is not an option in the genetic form.
The range of immunosuppressive therapies linked to AEV is broad, spanning calcineurin inhibitors, antimetabolites, biologics, tyrosine kinase inhibitors, and cytotoxic chemotherapy.20PubMed Central. Acquired Epidermodysplasia Verruciformis in Patients with Iatrogenic Immunosuppression For clinicians managing immunosuppressed patients, AEV is worth keeping in the differential when unusual flat warts or hypopigmented patches appear on sun-exposed skin.
Treatment and Its Limits
There is no cure for genetic EV, and that remains one of the most frustrating realities of the disease. The viral infection is lifelong because the underlying genetic defect that permits it cannot be corrected with currently available therapies. Management focuses on controlling lesions, monitoring for malignant change, and removing cancers or precancerous growths when they appear.
Photodynamic therapy (PDT), which uses a light-sensitizing agent applied to the skin followed by targeted light exposure, has shown some promise for clearing individual lesions. Early reports demonstrated that lesions treated with PDT healed without scarring and produced good cosmetic outcomes, though new lesions continued to appear.21PubMed. Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy More recent case reports have combined surgery to remove thick, verrucous plaques with follow-up PDT sessions to treat residual flat lesions, with one patient remaining recurrence-free at one year.22PubMed. Multiple Epidermodysplasia Verruciformis Successfully Treated by Surgery Combined with Photodynamic Therapy Another report described a patient whose EV had been resistant to multiple previous therapies and who achieved encouraging results with combined surgery and PDT.23PubMed. Successful treatment of epidermodysplasia verruciformis with a combination of 5-aminolevulinic acid photodynamic therapy and surgery
These results are encouraging but come from individual case reports, not controlled trials. Given how rare EV is, large trials are unlikely to happen anytime soon. Other treatments that have been tried include topical retinoids, systemic retinoids like acitretin, topical imiquimod (an immune-stimulating cream), cryotherapy, and conventional surgical excision. None of these produces lasting clearance. The most practical approach for most patients is regular skin surveillance to catch cancers early, aggressive sun protection, and targeted removal of lesions that are suspicious, symptomatic, or cosmetically distressing.
Experimental and Future Therapies
The most exciting lines of research for EV are still in early stages. Because the disease is caused by loss-of-function mutations in specific genes, gene therapy is a logical theoretical approach. CRISPR/Cas9 gene-editing technology, which could in principle correct the EVER1 or EVER2 mutation in skin cells, is under investigation as a potential future treatment.24PubMed. Clinical and Molecular Perspectives on Epidermodysplasia Verruciformis The technical challenges are substantial. The correction would need to reach enough keratinocytes across the body’s entire skin surface to make a durable difference, and delivering gene-editing tools to skin at that scale is not something anyone has achieved for any condition yet.
Zinc supplementation is another area of interest, which makes intuitive sense given the zinc-transport role of EVER proteins. The idea is that systemic or topical zinc might partially compensate for the disordered intracellular zinc distribution. This too is listed among experimental strategies being explored for EV, though published evidence of clinical benefit remains thin.25PubMed. Clinical and Molecular Perspectives on Epidermodysplasia Verruciformis Whether externally delivered zinc can mimic the precise intracellular compartmentalization that functional EVER proteins provide is an open question.
Living With the Condition
The physical aspects of EV are medically serious, but the psychological and social burden is often underappreciated. Widespread, visible skin lesions that begin in childhood, resist treatment, and carry a cancer risk create a heavy load. In communities unfamiliar with the condition, the appearance of EV lesions can provoke stigma and social isolation. The media’s tendency to frame severe cases with sensationalized “tree man” coverage has cut both ways: it has raised some awareness and funding interest, but it has also reinforced a freakish image that does not reflect most patients’ experience.
For families dealing with a new diagnosis, genetic counseling is valuable. Understanding the inheritance pattern helps families assess the risk for future children and for other relatives who may carry a single copy of the mutation. Because EV is rare enough that many general practitioners will never see a case, connecting with a dermatologist experienced in genodermatoses or with a specialized genetics center can make a meaningful difference in management quality and cancer surveillance planning. The rarity of EV means that every patient’s care team is, in a sense, building the playbook as they go.